Invention Grant
- Patent Title: Tricyclic heterocyclic compounds useful as inhibitors of TNF
-
Application No.: US15558708Application Date: 2016-03-17
-
Publication No.: US10308652B2Publication Date: 2019-06-04
- Inventor: Stephen T. Wrobleski , Gregory D. Brown , Shuqun Lin , Jingwu Duan , Zhonghui Lu , Murali T. G. Dhar , Hai-Yun Xiao , Andrew J. Tebben
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Gary Greenblatt
- International Application: PCT/US2016/022738 WO 20160317
- International Announcement: WO2016/149437 WO 20160922
- Main IPC: C07D487/14
- IPC: C07D487/14 ; C07D491/147 ; A61K31/5025 ; A61P37/00 ; C07D471/14 ; C07D487/06 ; A61P29/00 ; A61P27/00

Abstract:
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
Public/Granted literature
- US20180111937A1 TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF Public/Granted day:2018-04-26
Information query